STOCK TITAN

Allarity Therapeutics Inc - ALLR STOCK NEWS

Welcome to our dedicated news page for Allarity Therapeutics (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Allarity Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Allarity Therapeutics's position in the market.

Rhea-AI Summary
Allarity Therapeutics, Inc. announces a strategic pivot to focus on advancing stenoparib in advanced recurrent ovarian cancer, based on promising Phase 2 trial data. The company shifts resources to accelerate stenoparib development, deprioritizing IXEMPRA® and dovitinib. The decision aims to address an unmet medical need, reduce costs, and align with the growing PARP inhibitor market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
-
Rhea-AI Summary
Allarity Therapeutics, Inc. (NASDAQ: ALLR) receives a formal extension until April 24, 2024, to regain compliance under Nasdaq Listing Rules. The company has presented a strategic plan to address compliance deficiencies, focusing on achieving a stockholders' equity of at least $2.5 million and a minimum bid price of $1.00 per share for 10 consecutive business days. The plan includes cost reduction, liability conversion, and seeking additional capital to strengthen financial position and operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.25%
Tags
none
-
Rhea-AI Summary
Allarity Therapeutics, Inc. reported significant advancements in personalized cancer treatments in 2023, with a focus on stenoparib for advanced ovarian cancer. The company reduced net loss from operations by 50% and net loss by 26%. Key highlights include the appointment of Thomas Jensen as Interim CEO, data showing clinical benefit in ovarian cancer trials, and engagement of Jeremy Graff, Ph.D. as an Executive Advisor. Anticipated milestones for 2024 include the disclosure of interim data from the Phase 2 clinical trial of stenoparib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
earnings
Rhea-AI Summary
Allarity Therapeutics, Inc. has been invited to present at Biomarkers 2024, showcasing their innovative work on the Drug Response Predictor (DRP®) companion diagnostics platform. The CEO, Thomas Jensen, will discuss the application of DRP® in an ongoing ovarian cancer trial, aiming to identify patients likely to benefit from treatment. The company's presentation will shed light on their cutting-edge personalized cancer treatment approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.03%
Tags
conferences
-
Rhea-AI Summary
Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced a leadership transition with the appointment of Thomas H. Jensen as Interim CEO and the engagement of Jeremy R. Graff, Ph.D., as an Executive Advisor. Jensen brings two decades of experience and expertise to his new role, and Dr. Graff has over 25 years of experience in the biotech and pharma industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
management
-
Rhea-AI Summary
Allarity Therapeutics, Inc. (Nasdaq: ALLR) announces encouraging initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women with advanced ovarian cancer. Of the five evaluable patients, one experienced a complete response, and the other four demonstrated stable disease. The protocol change from once-daily to twice-daily dosing has shown early signs of clinical benefit in all cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
clinical trial
Rhea-AI Summary
Allarity Therapeutics, Inc. has been invited to present at Biomarkers Europe 2023, focusing on the development of drug-specific companion diagnostics for oncology therapeutics. They will also participate in a panel discussion with speakers from Merck and Roche. Additionally, the company will attend the ThinkEquity Conference in New York and is open to discussing business development opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
clinical trial
-
Rhea-AI Summary
Allarity Therapeutics publishes clinical validation of drug-specific companion diagnostic for dovitinib in renal cell carcinoma (RCC) patients, demonstrating improved clinical benefit compared to unselected patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.35%
Tags
none
Rhea-AI Summary
Allarity Therapeutics and FivepHusion have entered into a Clinical Collaboration Agreement to develop Deflexifol™ for the treatment of solid tumors. Allarity will use its drug-specific DRP® companion diagnostics to potentially select patients for clinical trials. Deflexifol™ is a reformulation of the chemotherapeutic agent 5-fluorouracil (5FU) and its biomodulator leucovorin (LV) to improve therapeutic activity. FivepHusion plans to start a phase 1b/2a study in H2 2023 to evaluate Deflexifol™ in combination with oxaliplatin and bevacizumab for unresectable metastatic colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
clinical trial
Allarity Therapeutics Inc

Nasdaq:ALLR

ALLR Rankings

ALLR Stock Data

1.93M
5.56M
0.02%
0.94%
9.94%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boston

About ALLR

oncology venture is a drug development company formed in 2012 dedicated to unlock the potential of new oncology products, and rescue failed drugs. our method improves the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines and improve success rates in oncology drug development.